Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
Key Highlights
- ➤DENALI Part 1b Cyclin E1-positive patients posted 15.9-month median overall survival
- ➤DENALI Part 2c enrollment scheduled to complete in November 2026
- ➤DENALI integrated topline readout expected in the first half of 2027
- ➤Cash, equivalents and marketable securities reached $228.9 million, funding into 1H 2028
- ➤Third-quarter net loss widened to $28.8 million from $26.7 million
Expert Statements
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“We designed complementary paths through DENALI and ASPENOVA to support our goal of bringing azenosertib to patients as quickly as possible.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“In light of an evolving landscape in PROC, we plan to discuss the DENALI data with the FDA in 2027 to assess the accelerated approval opportunity.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“Meanwhile, we continue to advance ASPENOVA at full speed, ensuring we are well positioned to support our regulatory strategy under either an accelerated or full approval pathway.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“With DENALI Part 2c enrollment completing this month, we expect a topline readout from DENALI in the first half of 2027 — a key potential value-creating catalyst ahead of ASPENOVA.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“Alongside our PROC program, our strategy includes advancing azenosertib as a combination therapy where we see meaningful therapeutic and scientific rationale.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer.”
* DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROC * DENALI Part 2c enrollment scheduled to complete in November 2026, with an integrated topline readout expected in 1H 2027 * $228.9 million in cash, cash equivalents and marketable securities as of September 30, 2026 provides runway into 1H 2028 to support execution of key milestones SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zentalis(®) Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.
"Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved," said Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals. "We designed complementary paths through DENALI and ASPENOVA to support our goal of bringing azenosertib to patients as quickly as possible. In light of an evolving landscape in PROC, we plan to discuss the DENALI data with the FDA in 2027 to assess the accelerated approval opportunity. Meanwhile, we continue to advance ASPENOVA at full speed, ensuring we are well positioned to support our regulatory strategy under either an accelerated or full approval pathway. With DENALI Part 2c enrollment completing this month, we expect a topline readout from DENALI in the first half of 2027 — a key potential value-creating catalyst ahead of ASPENOVA.
Get started
Create a free account to read the full story.